pdufa.bio
Home › CRL letters › March 2025

FDA complete response letters, March 2025

Page updated ·next FDA decision on the calendar ·Data as of Nov 10, 2026 12:55 AM ET

The FDA's public release of complete response letters holds 7 letters dated March 2025 (openFDA, last updated 2026-08-26). Of the 26 FDA decisions on PDUFA goal dates pdufa.bio tracked in March 2025, 5 were Complete Response Letters.

Released by the FDA, dated March 2025 · 7

Letter dateCompanyApplicationopenFDA statusLetter
2025-03-27Milestone Pharmaceuticals USA, Inc.NDA 218571Unapprovedletter (PDF)
2025-03-26CELLTRION, Inc.BLA 761377Unapprovedletter (PDF)
2025-03-20Jiangsu Hengrui Pharmaceuticals Co., LtdBLA 761308Unapprovedletter (PDF)
2025-03-20Elevar Therapeutics, Inc.NDA 216586Unapprovedletter (PDF)
2025-03-13Accord BioPharma Inc.BLA 761424Unapprovedletter (PDF)
2025-03-11Seikagaku CorporationBLA 761393Unapprovedletter (PDF)
2025-03-10Laurus Generics, Inc.NDA 217719Unapprovedletter (PDF)

Complete Response Letters among decisions pdufa.bio tracked · 5

FDA actionTickerDrugSource
2025-03-28MISTsource-verifieddecision page
2025-03-27EQsource-verifieddecision page
2025-03-24CGONprice-onlydecision page
2025-03-24AURAprice-onlydecision page
2025-03-10PHIOprice-onlydecision page
A Complete Response Letter is the FDA's notice that it will not approve an application in its current form; it is not a permanent rejection, and the sponsor can resubmit. The two counts come from different records and are not added together. ← February 2025 · April 2025 → · all released letters · every CRL decision we tracked